Daily Medical Update

Actinic keratosis

Friday, April 03, 2026

🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.

1. Comparative efficacy of photodynamic therapy versus conventional therapies for actinic keratosis: A systematic review and meta-analysis.

Photodiagnosis and photodynamic therapy (2025) - Meta-Analysis

Key Findings

  • At 12 months, 5-fluorouracil achieved higher complete clearance than PDT (74.7% vs 37.7%; RR 0.50, 95% CI 0.40-0.64; P < 0.001).
  • PDT matched cryotherapy overall yet cleared grade III lesions more effectively (56.9% vs 13.4%; P = 0.021) and caused less hypopigmentation (0%-3% vs 31%; P < 0.001).
  • Against imiquimod, PDT performed better in organ transplant recipients (78% vs 61%; P < 0.001) and delivered higher patient satisfaction (90% vs 61%; P < 0.003).

📋 Practice Implication: Use 5-fluorouracil when durable field clearance is the primary goal, and reserve PDT for patients with grade III lesions, transplant status, or strong cosmetic priorities.

2. PDT combined with liquid nitrogen cryotherapy is superior to PDT alone in Actinic Keratosis.

Photodiagnosis and photodynamic therapy (2025) - Randomized Controlled Trial

Key Findings

  • Initial complete clearance at 3 months was higher with liquid nitrogen plus PDT than with PDT alone (93.6% vs 68.4%; P < 0.05).
  • Sustained complete clearance at 6 months remained higher with combination therapy (95.1% vs 72.6%; P < 0.05).
  • Clearance improved versus PDT alone without a reported increase in safety concerns during follow-up.

📋 Practice Implication: For thicker or treatment-resistant AK clusters, add cryotherapy before PDT to improve short-term and sustained clearance instead of repeating PDT alone.

3. Human Papillomavirus Vaccination and Actinic Keratosis Burden: The VAXAK Randomized Clinical Trial.

JAMA dermatology (2025) - Randomized Controlled Trial

Key Findings

  • Median AK reduction was greater with HPV vaccination than sham at month 6 (47% vs 29%; P = .01) and month 12 (58% vs 47%; P = .05).
  • Total AK counts and thick AK counts were lower in the vaccinated group at 12 months (10.0 vs 16.0 total AKs, P = .02; 3.0 vs 5.0 thick AKs, P = .049).
  • Rates of new AKs and keratinocyte cancers did not differ significantly over 12 months versus sham.

📋 Practice Implication: HPV vaccination is not ready to replace standard AK therapy, but it may merit discussion as an adjunctive strategy or trial option in immunocompetent patients with very high lesion burden.

💡 Summary

Recent actinic keratosis evidence supports tailoring field therapy to durability goals, lesion burden, and patient context rather than using a single default approach. A 2025 meta-analysis found 5-fluorouracil more durable than photodynamic therapy for 12-month clearance, while PDT retained advantages for grade III lesions, transplant recipients, and cosmetic outcomes; a randomized trial also showed higher 3- and 6-month clearance when cryotherapy was added to PDT. An emerging sham-controlled trial suggests HPV vaccination may reduce lesion burden in heavily affected immunocompetent adults, although it did not lower new AK or keratinocyte cancer events over 12 months.

Generated from 112 PubMed abstracts · RCTs and Meta‑analyses only

Next topic: Decisional capacity assessment

Unsubscribe · Subscribe